← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Centro Internacional (Cideim)
Cali
$5,542,172
Total funding
10
Grants
Funding over time
peak $1.7M · FY2013–24$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,542,172 · 10
By mechanism
U19$3,055,176 · 6
D43$1,562,951 · 1
R01$673,576 · 1
R03$142,478 · 1
G11$107,991 · 1
Investigators at Centro Internacional (Cideim)
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Optimizing Surveillance and Treatment for Control of Cutaneous Leishmaniasis$566,695
U19 · FY2018 · AI
Optimizing Surveillance and Treatment for Control of Cutaneous Leishmaniasis$559,430
U19 · FY2019 · AI
Optimizing Surveillance and Treatment for Control of Cutaneous Leishmaniasis$556,314
U19 · FY2017 · AI
Optimizing Surveillance and Treatment for Control of Cutaneous Leishmaniasis$552,668
U19 · FY2020 · AI
Optimizing Surveillance and Treatment for Control of Cutaneous Leishmaniasis$539,134
U19 · FY2021 · AI
Integration of Translational and Implementation Research Training on Leishmaniasis and other Vector-borne and Emerging Infectious Diseases$299,534
D43 · FY2020 · TW
Integration of Translational and Implementation Research Training on Leishmaniasis and other Vector-borne and Emerging Infectious Diseases$297,958
D43 · FY2023 · TW
Integration of Translational and Implementation Research Training on Leishmaniasis and other Vector-borne and Emerging Infectious Diseases$297,940
D43 · FY2021 · TW
Integration of Translational and Implementation Research Training on Leishmaniasis and other Vector-borne and Emerging Infectious Diseases$297,783
D43 · FY2022 · TW
Integration of Translational and Implementation Research Training on Leishmaniasis and other Vector-borne and Emerging Infectious Diseases$294,736
D43 · FY2024 · TW
The Innate Immune Response As A Therapeutic Target For Cutaneous Leishmaniasis$210,955
U19 · FY2021 · AI
Parasite Drug Susceptibility in The Response To Anti-Leishmanial Treatment$198,783
U19 · FY2021 · AI
The Innate Immune Response As A Therapeutic Target For Cutaneous Leishmaniasis$188,573
U19 · FY2018 · AI
The Innate Immune Response As A Therapeutic Target For Cutaneous Leishmaniasis$167,031
U19 · FY2020 · AI
The Innate Immune Response As A Therapeutic Target For Cutaneous Leishmaniasis$161,918
U19 · FY2019 · AI
The Innate Immune Response As A Therapeutic Target For Cutaneous Leishmaniasis$158,078
U19 · FY2017 · AI
Macrophage drug transport and metabolism in the outcome of antileishmania therapy$134,877
R01 · FY2014 · AI
Macrophage drug transport and metabolism in the outcome of antileishmania therapy$134,832
R01 · FY2013 · AI
Macrophage drug transport and metabolism in the outcome of antileishmania therapy$134,828
R01 · FY2015 · AI
Macrophage drug transport and metabolism in the outcome of antileishmania therapy$134,699
R01 · FY2016 · AI